Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials.
about
QSAR based therapeutic management of M. tuberculosis.Pharmacologic Inhibition of Host Phosphodiesterase-4 Improves Isoniazid-Mediated Clearance of Mycobacterium tuberculosis.Mycobacterium tuberculosis Proteome Response to Antituberculosis Compounds Reveals Metabolic "Escape" Pathways That Prolong Bacterial Survival.Ocular Tuberculosis.
P2860
Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Moxifloxacin and gatifloxacin ...... of randomized clinical trials.
@ast
Moxifloxacin and gatifloxacin ...... of randomized clinical trials.
@en
type
label
Moxifloxacin and gatifloxacin ...... of randomized clinical trials.
@ast
Moxifloxacin and gatifloxacin ...... of randomized clinical trials.
@en
prefLabel
Moxifloxacin and gatifloxacin ...... of randomized clinical trials.
@ast
Moxifloxacin and gatifloxacin ...... of randomized clinical trials.
@en
P2093
P2860
P356
P1476
Moxifloxacin and gatifloxacin ...... of randomized clinical trials.
@en
P2093
Bingyan Zhang
Jialin Jin
Jingwen Ai
Lingyun Shao
Qiaoling Ruan
Shenglei Yu
Wenhong Zhang
P2860
P356
10.1038/EMI.2016.12
P577
2016-02-24T00:00:00Z